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Introduction 
 
 On November 4, 2013, 
health care giant Johnson & John-
son agreed to pay more than $2.2 
billion to resolve criminal and 
civil allegations of off-label mar-
keting of three of its prescription 
drugs: Risperdal, Invega, and 
Natrecor.1 The civil settlement 
with federal and several state gov-
ernments totaled $1.72 billion.2 
Further, criminal fines and forfei-
tures reached $485 million. This 
settlement was the second largest 
health care fraud settlement in 
United States history.3 Less than 
four months later, Endo Health 
Solutions, Inc., and its subsidiary, 
Endo Pharmaceuticals, Inc., 
agreed to pay $192.7 million to 
resolve criminal and civil claims 
for the off-label promotion of the 
drug, Lidoderm.4 In a statement 
about the settlement, Zane D. Me-
meger, United States Attorney for 
the Eastern District of Pennsylva-
nia, said, “pharmaceutical compa-
nies have a legal obligation to 
promote their drugs for only FDA
-approved uses.”5 But what about 
the companies’ constitutional 
right to free speech? The United 
States Court of Appeals for the 
Second Circuit has been the only 
circuit to hold that truthful, non-
leading off-label promotion6 is 
protected under the First Amend-
ment in United States v. Caronia.7 
Nevertheless, as evidenced by the 
recent Johnson & Johnson and 
Endo Health Solutions settle-
ments, the free speech defense 
introduced in Caronia does not 
seem to be too promising for 
pharmaceutical companies faced 
with allegations of off-label pro-
motion.  
 
United States v. Caronia 
 
When the United States 
Court of Appeals for the Second 
Circuit decided Caronia in De-
cember 2012, the case was hailed 
as a “landmark” decision.8 It cre-
ated a circuit split between the 
Second Circuit and every other 
federal circuit because the Second 
Circuit was the only one to hold 
that off-label promotion was pro-
tected free speech under the First 
Amendment. Until this decision, 
no court had held that off-label 
promotion by pharmaceutical and 
medical device manufacturers and 
their representatives was protected 
under the Free Speech Clause of 
the First Amendment. This de-
fense was not available when the 
Food and Drug Administration 
(“FDA”) prosecuted off-label pro-
motion for violating the misbrand-
ing provisions of the Food, Drug 
and Cosmetic Act (“FDCA”).  
The defendant in Caronia 
was convicted of conspiring to 
introduce a misbranded drug, 
Xyrem, into interstate commerce 
in violation of the FDCA. On ap-
peal, the defendant ultimately pre-
vailed on the grounds that the off-
label promotion of the drug was 
lawful and protected under the 
First Amendment. In a 2-1 deci-
sion, the Second Circuit held that 
prohibiting the lawful off-label 
marketing of a drug unconstitu-
tionally restricted free speech. 
Further, it held that the misbrand-
ing provision does not prohibit off
-label promotion. The Second Cir-
cuit was the first Federal Court of 
Appeals that interpreted the 
FDCA’s misbranding provision to 
not expressly prohibit off-label 
promotion.  
 
The Food and Drug Admin-
istration’s Views on Off-Label 
Promotion 
 
Before entering interstate 
commerce, new drugs are subject 
to approval from the FDA to be 
marketed for specific uses.9 Once 
the FDA approves a drug, physi-
cians are free to prescribe it for 
approved and unapproved, or “off
-label uses.”10 Under the FDCA, 
introducing any adulterated or 
misbranded drug into interstate 
commerce is prohibited.11 A drug 
is considered misbranded if its 
label does not have adequate di-
rections for use.12 “Adequate di-
rections for use” is defined as di-
rections under which laypersons 
“may use the drug safely and for 
the purposes for which it is in-
tended.”13 “Off-label use” refers 
to the use of a drug, or other prod-
uct, in a way that is not indicated 
on its FDA-approved label.14 This 
term is applied when a drug is 
used to treat a disease not indicat-
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ed on the FDA-approved label. In 
addition, “off-label use” is also ap-
plied when prescribing the drug for 
the indicated disease for a different 
dosage or for a different patient pop-
ulation than indicated on the FDA-
approved label.15 
The FDA has acknowledged 
that under certain circumstances, off
-label use may be appropriate, such 
as when it is used as medically-
necessary standard of care.16 The 
FDA has expressed reluctance to 
interfere with the practice of medi-
cine or create barriers to physicians 
exercising their best judgment when 
considering treatment options for 
patients.17 The FDCA expressly 
states that none of the provisions of 
the Act “shall be construed to limit 
or interfere with the authority of a 
health care practitioner to prescribe 
or administer any legally marketed 
device to a patient for any condition 
or disease within a legitimate health
-care-practitioner-patient relation-
ship.”18 
 The prohibition against off-
label promotion is mainly directed 
at pharmaceutical and medical de-
vice manufacturers and their 
agents.19 A free speech violation 
may exist when these manufacturers 
and their agents are prohibited under 
the Act, but physicians, and other 
entities, such as medical journals, 
are allowed to promote the off-label 
use of drugs. The intent of physi-
cians to promote a certain drug for 
an off-label use is presumably driv-
en by the best interests of the pa-
tient, whereas such promotion by a 
pharmaceutical company and its em-
ployees is driven by profit, not safe-
ty. By promoting off-label uses, 
dosage, and patient populations, 
drug companies are able to ex-
pand its market to a broader 
range of consumers and in-
crease profits. Following the 
2012 decision in Caronia, the 
Federal Government argues that 
off-label use is only evidence of 
misbranding.20 The govern-
ment’s argument is that promot-
ing an off-label use is evidence 
that the speaker is asserting an 
intended use.21 Because it is off-
label, the labeling of the drug 
does not bear adequate direc-
tions of this off-label use.22  
 
Impact of Caronia: The Use of 
the Free Speech Defense 
 
 Since the Caronia deci-
sion in December 2012, at least 
one medical device manufactur-
er has asserted that off-label 
marketing is constitutionally-
protected speech and is not a 
violation of the FDCA. This 
defense, however, has not been 
universally successful. Some 
courts adopted the Caronia de-
cision,23 while others found it 
was unpersuasive.24 The Caro-
nia decision demonstrates an 
expansion in commercial speech 
rights in the context of pharma-
ceutical and medical device 
marketing. Nevertheless, the 
case law following the decision 
suggests that the decision will 
not significantly impact off-
label promotion.  Recently, 
Medtronic, Inc. (“Medtronic”), 
a medical technology company, 
has faced numerous lawsuits 
involving its InFuse Bone Graft/
LT-Cage Lumbar Tapered Fu-
sion Device (“InFuse Device). 
As a defense in these cases, the 
company has utilized the Sec-
ond Circuit’s holding that off-
label promotion does not violate 
the FDCA. The FDA approved 
the InFuse Device after its rig-
orous premarket approval 
(“PMA”) process.25 The plain-
tiffs in the InFuse Device law-
suits against Medtronic con-
tended that it was the off-label 
promotion by Medtronic repre-
sentatives to physicians that in-
duced the physicians to perform 
the spinal surgeries using off-
label methods.26 Specifically, 
the plaintiffs alleged that the 
representatives encouraged the 
surgeons to implant only one 
component in the three-part In-
Fuse Device system and to use a 
posterior approach during sur-
gery, rather than the FDA-
approved anterior approach.27 
The plaintiffs claimed that the 
off-label promotion of the de-
vice was executed without fully 
disclosing all the adverse effects 
and risks of the off-label uses.28 
The plaintiffs further asserted 
“Until this decision, no 
court has held that off-label 
promotion … was protected 
under the Free Speech 
Clause of the First Amend-
ment.”  
Continued... 
the Caronia decision will affect 
government litigation tactics or 
enforcement efforts. Numerous 
pharmaceutical manufacturers 
have pled guilty to charges of vio-
lating the FDCA by promoting off
-label uses and have settled with 
the government.39 Following the 
Johnson & Johnson settlement, 
Attorney General Eric Holder 
stated that the settlement 
“demonstrates the Justice depart-
ment’s firm commitment to pre-
venting and combating all forms 
of health care fraud.”40 The gov-
ernment has adamantly prosecut-
ed manufacturers and their repre-
sentatives for off-label promotion 
in the past.41 Between 2003 and 
2007, the FDA issued 42 regula-
tory notices and demanded that 
drug manufacturers cease circu-
lating information about off-label 
uses.42 During this period, the De-
partment of Justice settled eleven 
criminal and civil cases involving 
off-label promotion.43  
The government decided 
not to bring the Second Circuit’s 
decision to the Supreme Court for 
further review. It did not believe 
that the Caronia decision will im-
pact the FDA’s ability to enforce 
the FDCA’s drug misbranding 
provisions.44 The likely reasons 
for the government’s unwilling-
ness to appeal the decision to the 
Supreme Court are two-fold. 
First, the Second Circuit’s deci-
sion in Caronia did not question 
the validity of the misbranding 
provisions of the FDCA or find a 
conflict between these provisions 
and the First Amendment. Sec-
 
label way. Since the plaintiffs 
could not identify specific instanc-
es of off-label promotion to the 
physicians, these courts adhered to 
the Supreme Court’s presumption 
in Buckman that physicians have 
the discretion to use drugs and 
medical devices in off-label ways 
as long as they are an appropriate 
course of treatment.36 
 Although the adoption of 
the Caronia holding in the Fourth 
and Fifth Circuit, as well as in a 
Minnesota state court, would ap-
pear to be evidence of the persua-
siveness of the holding in Caronia, 
this is not the opinion held by all 
courts. The Ninth Circuit decisions 
in a number of InFuse Device cas-
es37 and a decision in a Maryland 
state38 court reveal that the Second 
Circuit’s decision in Caronia is not 
binding on jurisdictions outside 
that circuit, and off-label promo-
tion can still be illegal under the 
provisions of the FDCA. These 
courts rejected the holding under 
Caronia and held that off-label 
promotion violated the FDCA out-
right. 
 Based on the district and 
state courts’ differing interpreta-
tions on whether the misbranding 
provision of the Act prohibits off-
label promotion, it is unlikely that 
that these two off-label approach-
es caused them to suffer from 
resultant injuries.29 These injuries 
ranged from severe bone growth, 
pain, numbness, and difficulties 
with certain motor function.30 
 Several United States Dis-
trict Courts31 and a Minnesota 
state court have followed the Sec-
ond Circuit’s decision in these 
InFuse Device actions. These 
courts have held that off-label 
promotion is not unlawful under 
the misbranding provision of the 
FDCA and subsequently rejected 
the off-label promotion and use 
claims asserted by the plaintiffs. 
The courts recognized that the 
FDCA does not prohibit all pro-
motion of off-label uses.32 The 
United States District Courts and 
the Minnesota state court identify 
Buckman Company v. Plaintiffs’ 
Legal Committee as binding au-
thority.33 The Supreme Court 
held that physicians are able to 
prescribe drugs and devices for 
off-label uses.34 Moreover, the 
Court recognized the importance 
of not interfering with the prac-
tice of medicine and allowing 
doctors to prescribe drugs and 
devices for uses that have not 
been approved by the FDA.35  
 In the above referenced 
Medtronic cases, the plaintiffs 
failed to establish a link between 
off-label promotion and their re-
spective injuries. The plaintiffs 
could not state the specific state-
ments made by Medtronic Inc., or 
its agents, which induced the 
physicians to use the device and 
perform the surgery in an off-
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ondly, the Second Circuit did not 
strike down the FDCA’s drug ap-
proval framework. Since the Ca-
ronia decision is only binding on 
courts with the Second Circuit, the 
government may not want to risk 
a broadly applicable decision by 
the Supreme Court—especially 
since the Supreme Court’s deci-
sion in Sorrell seems to be protec-
tive of pharmaceutical speech.  
 
Conclusion 
 
 Over a year has passed 
since Caronia. What was once 
hailed as a landmark decision, and 
what appeared to be an expansion 
in pharmaceutical speech, has had 
little persuasive effect on the pros-
ecution of off-label drug promo-
tion by pharmaceutical compa-
nies. The government has re-
mained steadfast in its commit-
ment to prosecute for violations 
under the misbranding provision 
of the FDCA and in targeting 
companies that promote drugs for 
uses that have not been approved 
by the FDA. Since Caronia, nu-
merous pharmaceutical companies 
have settled with the government 
for allegations of misbranding 
through off-label promotion, in-
cluding three settlements in the 
Second Circuit itself.45 Because 
settlements with pharmaceutical 
companies for off-label marketing 
have been so successful, there is 
little reason for the Department of 
Justice to abandon its tactic of ag-
gressive prosecution.46 Not only 
will the government continue to 
prosecute off-label promotion and 
regard it as a per se violation of 
the misbranding provision, but 
pharmaceutical manufacturers are 
also not optimistic that the Second 
Circuit decision will be a useful 
defense. Instead, pharmaceutical 
companies appear to prefer to set-
tle and plead guilty.  
 Furthermore, the govern-
ment has an alternate avenue to 
prosecute off-label marketing. It 
could allege that off-label promo-
tion violates the False Claims Act 
(“FCA”). Under this alternative 
claim, the government would al-
lege that a pharmaceutical compa-
ny promoted the sale and use of 
drugs for uses that are not FDA-
approved and not covered by the 
federal health care programs; thus, 
the promotion of off-label uses 
would result in the submission of 
false claims. Regardless of wheth-
er the government prosecutes off-
label promotion under the Food, 
Drug and Cosmetic Act or under 
the False Claims Act, it is evident 
that a free speech defense is weak 
at best. The “side effect,” or pre-
dicted results, of the Caronia de-
cision have not been as desirable 
as anticipated.  
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Introduction 
 
 It is no secret that Ameri-
cans are struggling with their 
health. The United States consist-
ently ranks among the top ten 
obese countries in the world.1 This 
epidemic has become extremely 
problematic for Americans: it is 
not just expensive but it is killing 
people. As the serious detrimental 
consequences to America’s health 
mount, state and local govern-
ments are attempting to fight the 
problem head on by implementing 
a number of policies that encour-
age Americans to curb their appe-
tite and make smarter choices 
when it comes to their health. 
Sugar sweetened beverages, par-
ticularly soda, have become a 
large target for these public health 
initiatives.2 Famously introduced 
by former New York City mayor 
Michael Bloomberg, probably the 
most restrictive health initiative 
called for a 16-oz cap on soda at 
restaurants, movie theatres, and 
sports venues.3  More frequently, 
state and local governments are 
attempting to impose a one to two 
penny-per-ounce tax on soda.4 As 
a consequence soda manufactur-
ers, often referred to as “Big So-
da,” are painted in a negative 
light.5 A clear comparison can be 
made between this campaign and 
the events surrounding the tobac-
co litigation of the 1990s.6 But, 
with the complex interaction of 
genes, lifestyle, culture, and socio-
economic status contributing to 
obesity, are narrow restrictive 
measures like a soda tax the key to 
improving America’s health?  
 
At a Glance: Obesity in America 
 
 The co-morbidity of obesi-
ty and chronic diseases makes the 
current obesity epidemic a very 
serious, not to mention expensive, 
problem for the United States.7 
Being overweight or obese drasti-
cally increases a person’s risk for 
a number of serious and chronic 
health problems, including coro-
nary heart disease, Type 2 diabe-
tes, certain types of cancer, and 
stroke.8 According to the World 
Health Organization, chronic dis-
eases are the leading cause of 
mortality in the world, making up 
60% of all deaths.9 In addition to 
the health risks, the estimated 
medical cost of obesity in Ameri-
ca is $147 billion per year.10 This 
cost is primarily attributed to the 
cost of treating the chronic diseas-
es that are closely connected to 
obesity, including the provision of 
prescription drugs. As obesity 
rates rise, so will the cost of deal-
ing with the negative effects of 
America’s weight gain.  
 
The Soda Tax 
 
 Lawmakers can point their 
fingers in many directions as to 
whom to blame for the high obesi-
ty rates in the United States.11  
Soda has been a relatively easy 
scapegoat for officials to focus 
upon. This is due not only to the 
general popularity and prevalence 
of these products, but also to the 
high sugar content of sodas and 
other sugar sweetened beverages 
and their almost complete lack of 
nutritional value. The typical 
amount of sugar in any given soda 
vastly surpasses the recommended 
daily intake, a main reason why 
sodas have been a large target of 
public health campaigns.12 The 
World Health Organization’s new-
est proposal recommends that the 
average person should consume 
no more than 25 grams of sugar a 
day (which amounts to about 6 
teaspoons).13 A 12 ounce can of 
Coke has 39 grams of sugar (a lit-
tle over 9 teaspoons of sugar).14 
 The soda tax is a relatively 
new development in the national 
effort to decrease obesity among 
American adults and children.15 
The tax is intended to reduce soda 
consumption, thus reducing daily 
sugar and caloric intake, which in 
theory would reduce average 
Body Mass Index (BMI).16 This 
past year alone there were 26 bills 
proposed across the United States 
relating to taxes on sugar-
sweetened beverages, including 
San Francisco, Chicago, Califor-
nia and Hawaii, though none of 
these have been passed.17  
 These taxes have been met 
with strong criticism. When re-
search was released showing the 
negative effects of smoking, a 
similar situation emerged.18 In one 
respect, it is hard not to compare 
the obesity epidemic to tobacco. 
The obesity epidemic, like the 
harmful side effects of smoking, 
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came as a shock to everyone.19 It 
took a number of years to estab-
lish the taxes and policies we have 
now for tobacco.20 Analogously, 
many people today do not see how 
soft drinks are harmful to them, 
and, even if they do, they are not 
willing to give them up. Consum-
ers often do not look at the nutri-
tion labels or if they do, they are 
unable to decipher them. Conse-
quently, many are not aware of the 
actual nutritional content of soda. 
In addition, many consumers who 
are aware that soda contains high 
levels of sugar or high fructose 
corn syrup still continue to drink 
soda regardless of its lack of nutri-
tional content.21 This lack of 
knowledge coupled with a lack of 
concern makes it difficult to con-
vince consumers that soda may be 
harmful to their health, just as 
with tobacco.22 Soda is also mar-
keted in much the same way to-
bacco was, targeting children and 
young adults who will grow up to 
be the main consumer base of 
these products.  
 The parallels between to-
bacco regulation and the new push 
to start regulating the eating habits 
of Americans are incredibly simi-
lar. This comparison signals that a 
tax on soft drinks could be just as 
effective as the tax on cigarettes 
has been, especially on consump-
tion by children and young 
adults.23 Since tobacco taxes have 
been in effect, studies have shown 
that the tax has been effective in 
reducing consumption, especially 
in young adults.24 The theory is 
that if the tax on tobacco has been 
so successful, it should similarly 
work to lower rates of consump-
tion for soda, a less addictive 
product.   
 
The Benefits and Detriments of 
Soda Taxes 
 
 Taxing soda seems to be a 
decent remedy to a small part of a 
larger problem. The only genuine 
concern of taxes like the soda tax-
es is that they are, in theory, im-
posing lifestyle choices onto con-
sumers by the government. Pro-
vided that the tax does not become 
an arbitrary exercise of govern-
ment power for the sole purpose 
of raising money at the expense of 
consumers or the businesses that 
manufacture and produce soda, a 
soda tax is a decently justifiable 
policy to consider. These penny-
per-ounce soda taxes will not be a 
substantial economic burden to 
any one group over another be-
cause they are relatively small.25 It 
is unclear whether soda taxes will 
do much to reduce actual con-
sumption, but it will generate con-
siderable revenue that could be 
used to mitigate the already high 
costs of healthcare or for pro-
grams that help educate the public 
about healthy lifestyles.26 While 
there is a strong link between soda 
consumption and weight gain, it is 
hardly the only culprit. Soda is not 
the magic solution that will solve 
the obesity epidemic in America, 
but it is a worthy starting point.  
 Probably the largest con-
cern these soda taxes raise is the 
underlying use of governmental 
power, and if public health is 
something that a government has 
the legitimate right to regulate. 
Many Americans resent the gov-
ernment imposing their beliefs 
about what a healthy lifestyle 
looks like, as shown by the over-
whelming backlash former mayor 
Bloomberg received with his 16-
oz soda cap which was ruled un-
constitutional (a ruling that is cur-
rently being appealed).27 The New 
York Supreme Court Appellate 
Division held in New York 
Statewide Coal. of Hispanic 
Chambers of Commerce v. New 
York City Dep't of Health & Men-
tal Hygiene that the Board of 
Health did not have the power to 
enact such a ban. The court looked 
to the legislature as the source of 
power to enact such a regulation.28 
While many of the soda taxes are 
proposed by state legislatures, not 
many have been passed, indicating 
that Americans seem to be re-
sistant towards government regu-
lation of health measures.29 These 
concerns are valid; imposing such 
a tax does incentivize behavior; 
however, there is a big difference 
between policies that restrict be-
havior among consumers and poli-
cies that incentivize behavior.  
 Opponents of the tax also 
Continued... 
argue that the tax will not only 
restrict consumer freedom but will 
negatively impact low-income 
populations; however, these con-
cerns are misguided. The opposi-
tion is concerned that the tax is 
potentially harmful primarily to 
low income households and also 
to non-obese consumers. Oppo-
nents believe that soda taxes are 
regressive, meaning they negative-
ly impact lower income house-
holds. These groups believe that 
the product’s increased cost as a 
result of the tax will be passed 
along to the consumers and not the 
producers.30 Low-income house-
holds already spend a large por-
tion of their monthly expenses on 
food and beverage costs and typi-
cally buy soda because it is cheap-
er than the alternative choices 
such as juice or milk.31 This 
means that the soda tax is an un-
necessary burden on a population 
that spends a considerable portion 
of their income on food and drink. 
Minority populations also dispro-
portionately purchase soda com-
pared to other groups.32 Beyond 
individuals with low-income and 
minorities, there is also concern 
that the tax is unfair to non-obese 
or overweight consumers.  By 
charging everyone the same re-
gardless of the consumer’s weight, 
the tax does not discriminate 
against overweight consumers and 
non-overweight consumers. Thus, 
the benefits for overweight and 
obese customers would be at the 
expense of non-overweight cus-
tomers. Because the purpose of 
soda taxes are to reduce obesity 
and mitigate the related health 
concerns associated with obesity, 
opponents argue that asking non-
obese people to finance this cost 
with a soda tax is unfair.33  
 The concern of individual 
freedom may be outweighed in 
this case by the overall concern of 
society’s health. Both the govern-
ment and Americans themselves 
are already feeling the impact of 
the obesity epidemic: obesity costs 
Americans a staggering $147 bil-
lion a year.34 This is not an arbi-
trary exercise of the government’s 
power; it is an attempt to ensure 
that Americans are healthy and not 
unnecessarily wasting their mon-
ey. Similar to tobacco, the nega-
tive health impact on a large scale 
necessarily gives the government 
the ability to intervene, to an ex-
tent, a precedent which has been 
set by tobacco itself.35 So long as 
the taxes are reasonable and mere-
ly incentivize rather than restrict, 
they are within the government’s 
interest to impose and can hardly 
be considered an undue restriction 
on the freedom of consumers.  
 Concerns over the impact 
on low income or non-obese per-
sons are misguided. A penny-per-
ounce tax is so small an increase 
in price that it will hardly make an 
impact (this, however, may raise 
the question of why have the tax at 
all).36 However, if a penny-per-
ounce tax did indeed make sodas 
expensive enough to become too 
costly for lower-income consum-
ers to afford, there are cheaper and 
healthier alternatives available to 
them. Economists believe that, in 
raising the price of items like soda 
that have no nutritional value, 
consumers will turn to healthier 
alternatives like milk which would 
be less expensive than soda after 
the tax increase.37 This makes the 
tax an incentive rather than a re-
striction and illustrates the main 
concept behind the idea of the so-
da taxes in general. Rather than 
impose a ban which may be seen 
as an over use of government 
power (as discussed above), the 
government can raise the price of 
non-nutritional foods compared to 
nutritional foods which might in-
centivize consumers to make 
healthier choices. In the end, the 
added cost onto sodas would pale 
in comparison to the $147 billion 
obesity already costs Americans 
every year.38  
 Additionally, the revenue 
generated by the soda tax can mit-
igate any unfair implications of 
the tax by taking the money 
gained by the tax and putting it 
back into low-income communi-
ties. The Yale Rudd Center for 
Food Policy and Obesity has de-
veloped a revenue calculator 
which calculates the estimated 
revenue a penny-per-ounce soda 
tax would generate for each state 
or major U.S. city.39  For instance, 
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New York City alone would gen-
erate an estimated $345 million in 
2014 from a soda tax. If these 
funds were returned to low-
income areas, the revenue may 
mitigate any disparities for low-
income households. For example, 
the recent California bill imposing 
a penny-per-ounce tax on soda 
proposes to put all revenue raised 
by the tax into the “Children’s 
Health Promotion Fund,” a pro-
gram that promotes children mak-
ing healthy choices in diet and 
exercise.40 The amount of money 
these bills would raise is enough 
to take notice. The revenue could 
go a long way to fund future pro-
grams or even mitigate some of 
the costs obesity has imposed on 
the healthcare system. For in-
stance, the money could help de-
crease the annual cost of 
healthcare due to chronic diseases 
caused by obesity, be put into re-
search, or be used to fund pro-
grams to educate low-income 
families on cost efficient ways to 
have a healthy diet. The potential 
benefit of such revenue is one of 
the main reasons soda taxes are 
popular among the state legisla-
tures.41    
 
Conclusion 
 
 America’s obesity epi-
demic will not go away anytime 
soon.  Soda taxes are but a small 
part in a sea of regulations and 
measures that the government has 
proposed to help with the effects 
of American obesity. Soda taxes 
may not be the best solution, but 
they do offer access to money that 
can be used to fund more success-
ful measures. Penny-per-ounce 
soda taxes are not likely to be 
very successful at curbing Ameri-
ca’s soda addiction. The taxes are 
a small increase in price that is 
unlikely to stop most from buying 
soda. If the government truly 
wanted to discourage behavior, 
they would have to drastically in-
crease the price of soda, much 
like it has done with the price of 
cigarettes.42 As research continues 
to show the negative effects of the 
obesity rates in America, citizens 
will be more likely to accept 
measures such as a soda tax. For 
now, however, the policy is met 
with resentment and resistance by 
the general public and is not like-
ly to be successful in changing the 
public’s attitude towards soda. If 
the federal and state legislatures 
can find better ways to incentivize 
“healthy” behavior rather than 
regulate unhealthy behavior, they 
will be more successful in pro-
moting health improvement 
measures. A popular place to start 
is with children. One new meas-
ure that the Obama administration 
has recently unveiled is a plan to 
ban all junk food advertisements 
in schools, including soda.43 Ulti-
mately, some regulation is neces-
sary. Public health measures will 
inherently include some sort of 
imposed restriction on an individ-
ual’s behavior, but the numbers 
show that American obesity has 
become too big to ignore and it is 
time for the government to get 
serious about getting healthy.  
 
Continued... 
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Introduction 
 
 A major issue surrounding 
the Patient Protection and Afforda-
ble Care Act (PPACA), often re-
ferred to as “Obamacare,” con-
cerns the nearly 12 million undoc-
umented immigrants currently liv-
ing in the United States and their 
ineligibility to apply for federal 
health care.1 Although federal law 
does not allow undocumented im-
migrants to apply for health care 
because of their illegal resident 
status, undocumented immigrants 
still have access to emergency 
medical care under federal law.2 
When it comes time to pay for the 
emergency medical care given to 
undocumented immigrants, provid-
ers often turn to Medicaid, specifi-
cally what is colloquially known as 
“emergency Medicaid” because 
Medicaid reimburses hospitals 
when patients are unable to pay for 
their emergency room bills. Fund-
ing for Medicaid is provided by 
United States citizen taxpayers, 
and it is estimated that 1.3 billion 
dollars of taxpayer money goes 
towards “emergency Medicaid.”3 
Because of the heated debate over 
illegal immigration in the United 
States and the heavy burden on 
taxpayers to support these illegal 
immigrants, the issue of extending 
federal health care to undocument-
ed immigrants is highly controver-
sial. This article considers why it 
would be beneficial to American 
citizens to allow illegal immigrants 
to have the right to apply for health 
care. 
 
The Difference Between Medi-
caid and “Emergency Medicaid” 
 
 Medicaid provides health 
coverage to “more than 50 million 
children, families, pregnant wom-
en, the elderly, and people with 
disabilities.”4 It is available in eve-
ry state and it pays for a “full set of 
services for children, including pre-
ventive care, immunizations, 
screening and treatment of health 
conditions, doctor and hospital vis-
its, and vision and dental care.”5 
Additionally, these services are of-
ten provided at no cost to families.6 
However, undocumented immi-
grants are not eligible for federally 
funded public health insurance pro-
grams such as Medicaid.7 There-
fore, when undocumented immi-
grants are not eligible under these 
circumstances to apply for Medi-
caid, they must resort to 
“emergency Medicaid” in order to 
seek professional medical treat-
ment. 
 The existence of 
“emergency Medicaid” does bene-
fit society as a whole, in that its 
purpose is to prevent the spread of 
communicable diseases and to en-
sure general health.8 In this con-
text, “emergency” means “sudden-
onset conditions that threaten life 
or could cause serious impair-
ment.”9 This is highly beneficial to 
every American citizen because 
immigrants travel from all different 
parts of the world and, in order to 
ensure public health from the vari-
ous strains of illnesses and diseas-
es, undocumented immigrants 
must be able to access medical ser-
vices. When an illegal immigrant 
is struck with these “emergency” 
conditions, they have the federal 
right to obtain medical services 
from hospitals, which in turn pro-
tects American citizens from these 
very conditions.10 Diane Rowland, 
executive vice president for the 
nonpartisan Kaiser Family Foun-
dation writes that “from the per-
spective of our health-care system, 
when people show up and they’re 
sick, the health-care system is ob-
ligated to take care of them.”11 It 
seems just and fair to provide 
these types of services to non-
citizens, whether they have en-
tered illegally or not. However, a 
much debated issue comes from 
how medical providers are afford-
ing to provide this medical care to 
undocumented immigrants. 
 After medical assistance, 
hospitals may try to bill the undoc-
umented immigrant patient first.12 
However, if the patient cannot pay 
for any reason, the hospital will 
turn to “emergency Medicaid” to 
recoup their costs.13 In 2011, the 
federal government paid out 1.3 
billion dollars under “emergency 
Medicaid”.14 Additionally, states 
paid “hundreds of millions of dol-
lars” to repay hospitals for these 
services.15 Sandhya Somashekhar 
wrote in the Washington Post, that 
a “large percentage” of the finan-
cial burden imposed on hospitals 
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is labor and delivery costs because 
the majority of patients that use 
“emergency Medicaid” are preg-
nant women.16 These costs likely 
will only increase as immigrants 
continue to enter the United States 
illegally. Therefore, there is a 
strong need for health care refor-
mation. Allowing undocumented 
immigrants to apply for federal 
health care would alleviate the bur-
den on taxpayers who fund 
“emergency Medicaid.”  
 
Why Illegal Immigrants Cannot 
Apply For Federal Health Care 
  
 The legal authorization to 
limit federal health care services to 
illegal immigrants comes from The 
Code of Federal Regulations of the 
United States. 42 C.F.R. § 440.255 
limits services available to illegal 
immigrants to certain circumstances 
and conditions.17 § 440.255(c) ad-
dresses aliens who are not lawfully 
admitted for permanent residency 
in the United States.18 The pertinent 
part states that an illegal alien must 
receive the services necessary to 
treat this condition: 
 The alien has, after sudden on     
 set, a medical condition
 (including emergency labor and 
 delivery) manifesting itself by 
 acute symptoms of sufficient 
 severity (including severe 
 pain) such that the absence of 
 immediate medical attention 
 could reasonably be expected 
 to result in:  (i) Placing the 
 patient's health in serious jeo- 
 pardy; (ii) Serious impairment 
 to bodily functions; or (iii) 
 Serious dysfunction of any 
 bodily organ or part…19 
This provision protects the safety 
of American citizens because if 
an undocumented immigrant is 
permitted to acquire medical care 
to prevent such symptoms that 
could be indicative of communi-
cable diseases, then undocument-
ed immigrants will not pose as a 
threat to American health safety. 
Therefore, though undocumented 
immigrants are not allowed ac-
cess to federal Medicaid, the fact 
that they have access to 
“emergency Medicaid” shows 
that undocumented immigrants 
still can obtain the vital medical 
care that they require. 
 Additionally, the Supreme 
Court in the 1976 case Mathews 
v. Diaz ruled that limits are 
placed on the ability of illegal im-
migrants to obtain medical bene-
fits and services.20 At the time, 
“in order to qualify for Medicaid 
benefits, a noncitizen had to be 
lawfully admitted to the United 
States and continuously reside 
therein for the five years preced-
ing application for benefits.”21 In 
Diaz, the Court found that Con-
gress is not required to provide 
every benefit it provides to citi-
zens to all aliens, nor must it ex-
tend identical benefits to every 
distinct class of alien.22 Patrick J. 
Glen, in his article titled “Health 
Care and the Illegal Immigrant” 
reasons that “The Constitution 
does not require identical treat-
ment for every individual in the 
United States, citizen or alien, or 
identical treatment across different 
classes of aliens.”23 The Diaz rul-
ing remains good law and can be 
cited as precedent that health care 
does not need to be extended to 
illegal immigrants. 
 Finally, in 1986, Congress 
enacted the Emergency Medical 
Treatment and Active Labor Act 
(EMTALA), which was meant to 
provide patients with access to 
emergency medical care and “to 
prevent hospitals from ‘dumping’ 
unstable patients that could not 
afford to pay for their care.”24 
Even though EMTALA refers spe-
cifically to hospitals with an 
Emergency Department, the feder-
al government has applied the law 
requirements to “all facilities that 
participate in the Medicare pro-
gram and offer emergency ser-
vices.”25 Therefore, over time the 
concept that undocumented immi-
grants cannot apply for federally 
funded public health insurance 
programs has been solidified, 
while simultaneously the ability 
for undocumented immigrants to 
obtain emergency care has been 
legally recognized in hospitals 
around the country.26 
 
Continued... 
“Emergency Medicaid” 
PPACA And “Emergency Med-
icaid” 
 
 Somashekhar writes that 
the issue of taxpayers subsidizing 
health care for undocumented im-
migrants will likely expand under 
Obamacare.27 Somashekhar de-
fines undocumented immigrant 
“emergency Medicaid” issues as: 
“reimbursement offered to hospi-
tals to provide emergency and 
maternity care to people who, 
based on their income and other 
factors, would be eligible for reg-
ular Medicaid if only they weren’t 
a) in the country illegally, or b) in 
the country legally but not lawful 
long enough to join Medicaid 
(five years).”28 Additionally, Phil 
Galewitz, in his article “How Un-
documented Immigrants Some-
times Receive Medicaid Treat-
ment” writes: 
      A little-known part of the state      
      -federal health insurance pro-   
      gram for the poor pays about       
      $2 billion a year for emergen-   
      cy treatment for a group of   
      patients who, according to    
      hospitals, mostly comprise   
      illegal immigrants. Most of it  
      goes to reimburse hospitals for    
      Delivering babies for women   
      who show up in their emer-  
      gency rooms, according to  
      interviews with hospital offi- 
      cials and studies.29 
Galewitz writes that this funding 
accounts for less than one percent 
of the cost of Medicaid and the 
percentage “underscores the polit-
ical and practical challenges of 
refusing to cover an entire class of 
people.”30  
 Galewitz uses Florida as 
an illustration of the impact of 
illegal immigrants in the health 
system.31 Galewitz cites Joanna 
Aquilina, the chief financial of-
ficer of Bethesda Healthcare Sys-
tem in Boynton Beach, Florida, 
who says: “We can’t turn them 
away.”32 Aquilina sees many ille-
gal immigrants because of the 
hospital’s proximity to farms that 
harvest sugarcane and other sea-
sonal crops.33  Galewitz writes: 
Nearly one-third of Bethesda 
Hospital East’s 2,900 births 
each year are paid for by 
Emergency Medicaid, the 
category that covers mainly 
illegal immigrants. The cate-
gory includes a small propor-
tion of homeless people and 
legal immigrants who’ve 
been in the country less than 
five years. Hospitals can’t ask 
patients whether they’re ille-
gal immigrants, but instead 
determine that after checking 
whether they have Social Se-
curity numbers, birth certifi-
cates or other documents.34 
Additionally, “one study of Medi-
caid spending from 2001 to 2004 
in North Carolina estimated that 
99 percent of emergency Medi-
caid recipients were illegal immi-
grants.”35 This demonstrates a real 
issue exists with the distribution 
of emergency Medicaid in the 
United States for illegal immi-
grants, which places a high finan-
cial burden on American taxpay-
ers. 
 
Why The United States Should 
Extend Health Care to Illegal 
Immigrants 
 
 Health care for illegal im-
migrants has become a hotly de-
bated topic, as the United States 
has been unable to curtail the in-
flux of illegal immigrants from 
several countries around the 
world. PPACA is part of the U.S. 
Department of Health & Human 
Services (HHS). Observing the 
aims of the current health reform, 
the website for HHS makes it 
clear that only Americans are cov-
ered. HHS states: “The mission of 
the Department of Health and Hu-
man Services is to help provide 
the building blocks that Ameri-
cans need to live healthy, success-
ful lives.”36 Further, the website 
writes: “The Department of 
Health and Human Services 
(HHS) is the United States gov-
ernment’s principal agency for 
protecting the health of all Ameri-
cans and providing essential hu-
man services, especially for those 
who are least able to help them-
selves.”37 This issue, however, 
goes well beyond an isolated ar-
gument for allowing undocument-
ed immigrants the right to health 
care. 
 Some pundits argue that 
access to health care is a basic hu-
man right, analogous to education 
and employment.38 Michael J. 
McKeefery in his article, “A Call 
to Move Forward: Pushing Past 
the Unworkable Standard That 
Governs Undocumented Immi-
grants’ Access to Health Care Un-
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der Medicaid” writes that one per-
spective is to realize that undocu-
mented immigrants are human be-
ings and “it is their moral right to 
have access to services that are es-
sential to sustaining life.”39 Fur-
ther, some undocumented immi-
grants are children who have had 
no choice but to follow their par-
ents.40 Therefore, it would seem 
unfair to deny these basic human 
rights to innocent children. Finally, 
scholars contend that undocument-
ed immigrants are found to pay 
more in taxes than they collect in 
benefits; many undocumented im-
migrants stay in the United States 
for a “substantial period of time” 
and thus contribute much to their 
communities by paying taxes.41 
Therefore, undocumented immi-
grants serve as a valuable asset to 
the economy.  
 The other side of the argu-
ment is that undocumented immi-
grants should not be entitled to ap-
ply for Medicare because the cost 
considerations justify excluding 
undocumented immigrants from 
coverage.42 McKeefery writes that 
“tax-supported services, like feder-
al health care plans, cannot sustain 
the increase in demand that would 
result if undocumented immigrants 
were included in public health care 
programs.”43 Other substantial ar-
guments are that immigrants who 
reside illegally in the United States 
should not be allowed to receive 
the benefits of health care coverage 
because undocumented immigrants 
do not usually pay taxes to support 
federal programs.44 Finally, 
McKeefery argues that by denying 
coverage to undocumented immi-
grants, it would “likely create a dis-
incentive for individuals to enter 
the United States illegally.”45 Thus, 
there is a strong argument for con-
tinuing to bar undocumented immi-
grants ability to apply for Medicare 
and to further restrict undocument-
ed immigrants access to 
“emergency Medicare.” 
Considering both sides of 
the debate, it is hard to deny what 
the United Nations, of which the 
United States is a charter member, 
considers to be fundamental and 
basic human rights. Article 25 of 
The Universal Declaration of Hu-
man Rights protects the right to 
adequate medical care: 
Everyone has the right to a 
standard of living adequate for 
the health and well-being of 
himself and of his family, in-
cluding food, clothing, housing 
and medical care and necessary 
social services, and the right to 
security in the event of unem-
ployment, sickness, disability, 
widowhood, old age or other 
lack of livelihood in circum-
stances beyond his control.46 
The purpose of the United Nations 
is to “achieve its goals and coordi-
nate efforts for a safer world for 
this and future generations.” In 
addition, the UN has provided an 
Article that specifically addresses 
the need to provide all humans 
with adequate medical care. Since 
the Untied States is a charter mem-
ber of the UN, how does the Unit-
ed States have any right to deny 
this emergency medical care to 
undocumented immigrants on 
American soil?47 
 
Conclusion 
 
There are certainly many 
powerful and compelling argu-
ments on both sides of the debate. 
However, from a humanitarian 
perspective, it seems that the only 
fair and reasonable solution to this 
issue is to extend the ability to ap-
ply for Medicare to undocumented 
immigrants because it would elim-
inate the issue of American tax-
payers needing to pay for immi-
grant medical care and also allow 
undocumented immigrants to take 
the necessary steps in order to cov-
er themselves when future medical 
ailments arise, thus protecting na-
tional health and economy. There-
fore, eligibility for all federal 
health care programs ought to ex-
tend to undocumented immigrants.  
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“[O]ne study of Medicaid 
spending from 2001 to 2004 
in North Carolina estimat-
ed that 99 percent of emer-
gency Medicaid recipients 
were illegal immigrants.” 
President Obama’s Notable Advance toward Battling Health 
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 Health care fraud is a 
white-collar crime that involves 
the filing of dishonest health care 
claims in order to make a profit. 
This fraud occurs in many ways 
and the list encompasses individu-
als obtaining subsidized or fully-
covered prescription pills that are 
medically unnecessary and then 
selling them on the black market 
for a profit; billing by practition-
ers for care that they never ren-
dered; filing duplicate claims for 
the same service rendered as well 
as countless others.1  In fact, the 
ways to defraud are continuously 
increasing while detection has be-
come increasingly more difficult.2 
Health care fraud costs the coun-
try an estimated $80 billion dol-
lars a year and that figure has 
been growing exponentially. Due 
to this fact, health care fraud has 
been attracting political attention 
and was most recently placed to 
the legislative forefront by Presi-
dent Obama.  The graph shows 
the increase of health care fraud 
prosecutions in the last 20 years. 
As is readily apparent, Obama’s 
administration has been the most 
efficient and proactive with re-
gards to combating health care 
fraud.  President Obama’s efforts 
to ramp up the fraud and abuse 
investigations resulted in $4.1 bil-
lion recovered in 2011.3 The in-
creasing number of prosecutions 
shows that the steps the President 
has taken including expanding the 
Health Care Fraud Prevention and 
Enforcement Action Team 
(HEAT), increasing the punish-
ment  for those accused,  and less-
ening the standard required for 
prosecution of health care fraud 
cases, which have all proven to be 
effective in tackling fraud within 
our health care system. 
 President Obama has spe-
cifically addressed the issue of 
fraud in relation to Medicare in-
surance. Medicare and Medicaid 
programs comprise the largest sin-
gle purchaser of health care in the 
world, and account for over twen-
ty percent of all U.S. federal gov-
ernment spending.4  Thus, much 
of the fraud that occurs is targeted 
at Medicaid and Medicare insur-
ance providers. HEAT is at the 
forefront of investigating and 
prosecuting for such crimes. Since 
the creation of HEAT in 2009, the 
Medicare Fraud Strike Force, (a 
branch of HEAT) has expanded 
from 2 to 9 locations and more 
than 320 defendants were charged 
with allegedly billing more than 
one billion dollars in false claims. 
The locations now span the entire 
country with offices in the follow-
ing states: Louisiana, New York, 
Illinois, Texas, Michigan, Califor-
nia and Florida.5  
The Patient Protection and 
Affordable Care Act of 2010 
(PPACA) has revised preceding 
provisions dealing with health 
care fraud. One goal of the revi-
sion was to disincentivize this 
type of fraudulent behavior by 
increasing the level of punish-
ment. Specifically, there has been 
a two-level increase in the offense 
level for any defendant convicted 
of a federal health care offense 
relating to a government health 
care program which involves a 
loss of up to $1 million; a three-
level increase in the offense level 
for any defendant convicted of a 
federal health care offense relat-
ing to a government health care 
program which involves a loss of 
up to $7 million and  a four-level 
increase in the offense level for 
any defendant convicted of a fed-
eral health care offense relating to 
a government health care program 
which involves a loss of up to $20 
million.6  So what would have 
previously been punished on a 
scale of a misdemeanor has the 
possibility of being punished as a 
felony. Increasing the risk associ-
ated with committing such a 
crime is thought to be proportion-
ate with a reduction of such 
crimes.  
 President Obama, through 
the PPACA, has also lessened the 
standard of criminal culpability 
required for the prosecution  of 
health care fraud cases.7 Specifi-
cally, there has been a diminished 
requirement in terms of the mens 
rea—the subjective intent—
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violations can now occur 
whether or not the 
individual has actual 
knowledge or specific intent 
to commit a violation.” 
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required for prosecution of health 
care fraud cases. Prior to the pas-
sage of the PPACA, a conviction for 
health care fraud under 18 U.S.C. § 
1347, required the government to 
prove that the defendant: (1) know-
ingly and willfully executed, or at-
tempted to execute, a scheme or ar-
tifice; to (2) defraud a health care 
benefit program or to obtain by false 
or fraudulent pretenses any money 
or property under the custody or 
control of a health care benefit pro-
gram; (3) in connection with the de-
livery of or payment for health care 
benefits, items, or services.8  The 
passage of PPACA has relaxed the 
scienter–guilty knowledge— re-
quirement by inserting subsection 
(b), which states: “With respect to 
violations of this section, a person 
need not have actual knowledge of 
this section or specific intent to 
commit a violation of this section.”9 
This wording encompasses a broad-
er range of violations by not requir-
ing intent to commit.  Simply put, 
prior to PPACA the government had 
to prove that an individual knowing-
ly and willfully executed, or at-
tempted to execute, a fraudulent 
scheme or artifice. PPACA has low-
ered the bar for the prosecution by 
relaxing that standard. Violations 
can now occur whether or not the 
individual has actual knowledge or 
specific intent to commit a viola-
tion. If fraud occurred, the person 
will be held accountable.  
As can be seen from the 
aforementioned examples, President 
Obama has stepped right into the 
forefront of America’s battle with 
health care fraud.  Over the past few 
years, we have seen a  75% in-
crease in the number of individu-
als whom we have charged with 
criminal health care fraud due to 
actions by HEAT and the prose-
cution of more than 1,400 de-
fendants who collectively falsely 
billed the Medicare program 
more than $4.8 billion.10 
In conclusion, the number 
of agencies dealing with health 
care fraud has increased and there 
has been more severe punishment 
for those convicted of health care 
fraud. In addition, the standard of 
culpability needed for the prose-
cution of health care fraud cases 
has been reduced.  These changes 
have been successful initiatives  
in battling health care fraud.  
Continued... 
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Healthcare providers are 
establishing electronic health record 
(EHR) systems at an astonishing 
rate, due in part to the Health Infor-
mation Technology for Economic 
and Clinical Health (HITECH) Act. 
The HITECH Act was created as a 
part of the American Recovery and 
Reinvestment Act of 2009.1  The 
$27 billion dollar piece of legisla-
tion offers eligible providers incen-
tives for expanding the use of 
healthcare information technology 
(HIT).2 This includes promoting the 
“meaningful use” of EHRs. The 
“meaningful use” standard was de-
signed to use HIT to improve quali-
ty of care and health outcomes for 
patients, as well as to lower costs 
by eliminating repeat medical tests 
and reducing preventable medical 
errors that pervade the health-care 
system today. This legislation has 
been extremely effective in per-
suading healthcare providers to use 
EHRs. In fact, the incentives out-
lined in the HITECH Act are esti-
mated to increase EHR adoption 
rates to 90% of all physicians by 
2019.3 Despite healthcare technolo-
gy’s vast potential to improve pa-
tient health in the medical arena, a 
host of complex legal, technical, 
and ethical issues surrounding the 
use of HIT as incentivized in the 
HITECH Act still exist, specifically 
privacy, confidentiality, autonomy, 
and the preservation of the physi-
cian-patient relationship. By reeval-
uating, clarifying, and enforcing 
HIPAA guidelines as they pertain 
to secondary use of EHRs, re-
searchers can access large valuable 
data sets without compromising 
patients’ rights to privacy and au-
tonomy. However, EHRs cannot be 
considered a cure-all for patient 
health. We must acknowledge the 
potential detrimental effect it may 
have on the physician-patient rela-
tionship. It is important to provide 
patients with the right to dictate 
which information they choose to 
share and allow them to opt out of 
the platform to protect patient au-
tonomy while optimizing the re-
search potential of electronic health 
data.  
 
The HITECH Act and 
“Meaningful Use” 
 
The HITECH Act offers 
hospitals and eligible healthcare 
professionals incentives for ex-
panding the use of healthcare infor-
mation technology, including the 
“meaningful use” of EHRs.4 Incen-
tive payments are made available 
through the Medicaid and Medi-
care programs. The Centers for 
Medicare & Medicaid Services 
(CMS) judges whether a healthcare 
provider has satisfied the meaning-
ful use core objectives through the 
use certified health technologies. 
The Department of Health 
and Human Services (HHS) defines 
“meaningful use” as using certified 
EHR technology to: (1) improve 
quality, safety, efficiency, and re-
duce health disparities; (2) engage 
patients and families; improve care 
coordination, and population and 
public health; and (3) maintain pri-
vacy and security of patient health 
information.5 This “meaningful 
use” framework incentivizes im-
provements to clinical care and 
quality by encouraging healthcare 
professionals to take advantage of 
instantaneous and patient-specific 
information.  
There are three stages of 
“meaningful use.” The first stage is 
the use of HIT for basic data collec-
tion, including demographic and 
medication history. The second 
stage is the use of EHR data to im-
prove clinical processes including 
patient controlled data, clinical de-
cision support, health information 
exchange, and quality measurement 
and research. The third stage is the 
use of EHR data to improve health 
outcomes, quality, safety, efficien-
cy, and population health at the na-
tional level.6 Hospitals and provid-
ers eligible for the EHR Incentive 
Program do not need to attest to 
meaningful use in their first year of 
participation. Rather, healthcare 
entities must simply implement an 
EHR to receive an incentive pay-
“[T]he secondary use of 
health data for research has 
great potential to improve 
health outcomes, reduce 
medical errors, predict 
health trends, and demon-
strate the comparative val-
ue of drugs and other treat-
ments.” 
Continued... 
 ment from their State. 
 The HITECH incentive pay-
ments are quite substantial. To re-
ceive payments, eligible profession-
als and hospitals must meet at least 
5 of the “meaningful use” criteria 
defined, consisting of 15 core data 
points and 10 menu options.7 The 
criteria require the entry of patient 
demographic and insurance infor-
mation, e-prescribing, and the use 
of drug interaction software to en-
sure patient safety. 8 Eligible profes-
sionals and hospitals that meet the 
criteria can be rewarded up to 
$44,000 in Medicare and $63,750 in 
Medicaid payments over 5 years. 
After 2015, all physicians who fail 
to meaningfully use EHRs will be 
subject to reductions in Medicare 
and Medicaid reimbursement.9 
 
Health Information Exchanges 
 
The HITECH Act is a step 
towards the eventual goal of a na-
tional, interoperable, private, and 
secure electronic system to allow 
information to be shared among all 
the sites where patients receive 
care.10  While still in its infancy, 
Health Information Exchanges 
(HIEs) are being established at the 
community, state, and national level 
to facilitate the electronic exchange 
between systems. The State Health 
Information Exchange Cooperative 
Agreement and the Nationwide 
Health Information Network 
(NHIN) received $600 million in 
federal funding to create a platform 
for health information exchange 
across the United States.11 At the 
state level, governments are creat-
ing statewide health information 
networks (HINs). At the national 
level, the Office of the National 
Coordinator (ONC), which over-
sees deployment of the HITECH 
Act, is executing plans to create an 
NHIN. Provider organizations par-
ticipating in NHIN include Kaiser 
Permanente, the Cleveland Clinic, 
and the Veterans Administration.  
These networks can lead to 
the development of data reposito-
ries filled with rich sets of health 
data for millions of individuals. 
Such data repositories can provide 
researchers with information nec-
essary to improve quality of care 
and make significant discoveries in 
medicine that they may not other-
wise have access to. Despite their 
great potential, progress in devel-
oping HIEs and repositories has 
been gradual. Many hospitals and 
clinics are hesitant to implement 
the systems because they do not 
have the finances or infrastructure 
necessary to do so.12 Moreover, 
there are also significant concerns 
over patient privacy and autonomy.  
 
Secondary Use of Health Data 
 
 Until recently, collecting 
data for “secondary use” was an 
arduous task. “Secondary use” in 
healthcare is defined as the use of 
information collected from health 
records, electronic or manual, out-
side of direct patient care delivery. 
This includes data collection for the 
purpose of “research, quality and 
safety measurement, public health, 
payment, provider certification or 
accreditation, marketing, and other 
business applications.” 13 Such use 
of healthcare data in biomedical 
research has the potential to drasti-
cally improve the quality and af-
fordability of healthcare services in 
the United States. EHRs contain 
structured information about pa-
tients, which is extremely valuable 
in research because now infor-
mation can be retrieved in a much 
quicker and more efficient fashion 
than more traditional methods of 
record keeping. Researchers can 
develop algorithms to search 
through EHRs, including free-text 
clinician notes, to find data valuable 
to a specific study.14 
By providing researchers 
with rich ready-made large data 
sets, the secondary use of health 
data for research has great potential 
to improve health outcomes, reduce 
medical errors, predict health 
trends, and demonstrate the com-
parative value of drugs and other 
treatments.15 Other benefits include 
the increased ability to analyze the 
efficacy of treatment options and 
identify evidence-based best prac-
tices. Furthermore, predictive mod-
eling techniques may be applied to 
electronic health data to identify 
medical conditions before the onset 
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 of symptoms and promote earlier 
interventions. While experimental 
studies, such as randomized con-
trolled clinical trials, are likely to 
continue to be the gold standard of 
clinical research compared to ob-
servational studies, they are more 
expensive and time consuming. As 
such, electronic health data serves 
as a rich resource for the conduc-
tion of valuable observational stud-
ies which can be performed quickly 
and inexpensively. 
Nevertheless, the unprece-
dented surge in the amount of 
healthcare data, as well as the rela-
tive ease with which that data can 
be aggregated and exchanged be-
tween providers and researchers, 
raises ethical questions about its use 
in research, particularly concerning 
patient privacy and autonomy.  The 
Health Insurance Portability and 
Accountability Act (HIPAA) re-
quires protected health information 
(PHI) to be de-identified or author-
ized by the patient for release in 
order to be used in research. How-
ever, de-identified data would 
omit significant clinical, demo-
graphic, and time-related data that 
would render the data sets much 
less useful for many research pur-
poses. While de-identified data 
leads to incomplete data sets, it 
seems like a small price to pay for 
protecting the privacy of patients, 
especially those with stigmatized 
conditions. 
Accordingly, researchers are 
forced to walk a fine line between 
ensuring patient privacy 
and maximizing the descriptive 
power of their data sets.  Before the 
research value of secondary use 
can be fully realized, ethical con-
siderations surrounding the min-
ing of electronic health data must 
be explored, namely infringe-
ments on an individual's privacy, 
confidentiality, and autonomy. It 
is necessary to establish a nation-
al framework of policies for the 
secondary use electronic health 
data to allow stakeholders to har-
ness valuable information to im-
prove the United States’ 
healthcare systems while main-
taining patient autonomy and pri-
vacy protections.16 
 
Data Quality Concerns 
 
The mass amount of re-
cent electronic health data makes 
it possible to assess the overall 
burden of disease and evaluate 
the impact of interventions on a 
national scale. Despite its prom-
ise, research through electronic 
health data mining and 
“secondary use” is not without 
flaws. Data quality concerns are 
inherent in data that is being used 
for any purpose other than what it 
was originally intended, especial-
ly considering the fragmented na-
ture of the healthcare industry and 
the numerous platforms on which 
data is being collected.17 First, 
there are hundreds of different 
EHR systems, each with a distinct 
representation of data that makes 
it difficult to aggregate.18 Second, 
even within the same EHR sys-
tem, information incompleteness, 
inaccuracy, and inconsistency are 
common challenges.19 Different 
healthcare professionals tend to 
use the same system differently.20 
Third, clinicians tend to prefer us-
ing free text compared to struc-
tured data entry because it is more 
easily adapted to their individual 
practice styles and work flows, 
although it may make it more dif-
ficult to compile and analyze.21 
Fourth, incomplete and duplicate 
records threaten the quality of re-
search using data mined from 
EHRs.  
Some critics may argue 
that EHRs make it more possible 
for clinicians to falsify charts and 
reports, which would lead to both 
data quality and trust issues with 
patients. However, the falsification 
of records would not only violate 
the moral imperative against lying, 
but also infringe on the fiduciary 
relationship between the physician 
and patient.  Furthermore, there are 
methods to protect against such 
acts, including audits, fraud charg-
es, and reclamation of funds under 
the False Claims Act and the Defi-
cit Reduction Act.22 These 
measures are valid disincentives to 
data falsification when it comes to 
patient records.  
Lastly, while the incentives 
and mandates of HITECH and 
“meaningful use” have led to an 
enormous amount of data being 
stored and generated by the U.S. 
healthcare system, there is an ex-
treme lack of interoperability. The 
electronic data exists in different 
formats on hundreds of different 
systems. Aggregating this sizeable 
amount of data for research pur-
poses will prove difficult, if not 
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 impossible, without a national regu-
latory framework to reduce inter-
system variation and improve data 
quality. The federal government 
must determine national data stand-
ards or guidelines and clinicians to 
decrease data variation between 
systems.23 By implementing legis-
lation to address these issues, the 
federal government can alleviate 
many ethical concerns while allow-
ing the United States healthcare 
system to benefit from more effec-
tive and larger scale use of second-
ary data. 
 
HIPAA and Privacy Concerns 
 
With improved access to 
data comes increased risk of wrong-
ful disclosure of patient health in-
formation. Human error, hacking, 
IT glitches, and theft or loss of 
hardware that contains such infor-
mation are just a few possible risks. 
HITECH challenges certain notions 
of privacy and security found in 
HIPAA yet enhances others. 
HIPAA prohibits the disclosure of 
protected health information (PHI) 
without the consent of the patient 
except for the purposes of treat-
ment, payment, or healthcare opera-
tions. Under HIPAA, “business as-
sociates” of covered entities with 
access to PHI are not directly regu-
lated.24 Rather, they are obliged to 
comply with HIPAA pursuant to 
mandatory written agreements 
within the covered entities for 
which they work. The HITECH 
Act, on the other hand, provides for 
regulation of business associates 
and stipulates that HIPAA’s priva-
cy and security rules directly ap-
ply to them. 
When it comes to security 
breaches involving PHI, HITECH 
mandates public notification 
when unsecure, unencrypted PHI 
is disclosed or used for an unau-
thorized purpose, similar to many 
state and federal financial data 
breach laws. The HITECH Act 
also requires that patients be noti-
fied of both internal and external 
breach of their data security. If a 
breach affects over 500 patients, 
HHS must also be notified and 
the name of the breaching institu-
tion will be posted on the HHS 
web site. There are also certain 
circumstances where local media 
will need to be notified to inform 
the public of breaches than effect 
many people within a given ar-
ea.25   
 While HITECH is a feder-
al law, HHS and state officials are 
granted with the authority to en-
force the law. Subtitle D of the 
HITECH Act addresses the priva-
cy and security concerns of EHRs 
by strengthening both the civil 
and criminal enforcement of the 
HIPAA rules.26 Section 13410(d) 
of the HITECH Act revised the 
Social Security Act by establish-
ing significant penalties for viola-
tions of security policy of the 
HITECH Act.27 If an institution 
or individual is unaware of a viola-
tion despite due diligence, the 
minimum penalty is $100 per vio-
lation, with a cap of $25,000 for 
violations of an identical require-
ment within the same year.28 If the 
security violation is due to “willful 
neglect,” the minimum penalty is 
$10,000 per violation, with a cap 
of $250,000.29 The maximum pen-
alty is $50,000 per violation, with 
a cap of $1.5 million.30  These are 
clear examples of the HITECH’s 
acts attempts to deter data breach-
es and mitigate security concerns. 
The healthcare industry 
continues to tread carefully when 
it comes to pursuing “meaningful 
use” of HIT while protecting pa-
tient privacy under HIPAA regula-
tions. Some argue, however, that 
the current HIPAA regulations do 
not accommodate the powerful 
research opportunities that may 
become possible as HIT and HIEs 
become more commonplace. The 
public health benefits of secondary 
use merit careful consideration of 
how such data can be optimized 
while protecting patient autonomy. 
 
Autonomy, Informed Consent, 
and Syndromic Surveillance  
 
Several ethical considera-
tions must be addressed before a 
national framework is implement-
ed to address issues of autonomy 
and informed consent. Patient au-
tonomy is threatened when an in-
dividual’s PHI is shared without 
that person’s knowledge or con-
sent. When data mining electronic 
health data, it is unlikely that pa-
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 tients are told that their data is be-
ing accessed. It is even less likely 
that they are contacted for their 
consent.  
This is concerning, as cham-
pions of patient autonomy argue 
informed consent is necessary for 
the secondary use of health data. 
Patients often believe they have a 
right to know who is viewing their 
medical information, why it is be-
ing accessed, and how it is being 
used. Additionally, those who 
champion patient autonomy believe 
that patients have a right to take an 
active part in decisions about the 
access, content, and ownership of 
EHR data. It would appear to be a 
violation of autonomy to aggregate 
and generate new information about 
a patient’s health without their 
knowledge or permission. Patients 
provide information to healthcare 
professionals in confidence with the 
specific goal of advancing their 
own personal health outcomes.  If 
the principle of autonomy is intrin-
sically linked to advancing an indi-
vidual’s own personal health out-
comes, then any form of secondary 
use (by definition as the use of PHI 
outside of direct patient care deliv-
ery) appears to be a violation of the 
principle of “respect for persons.” 
A critical question here is whether 
or not you can turn a patient into a 
research subject without their 
knowledge or consent. 
To overcome these issues of 
autonomy, patients should be able 
to access their EMRs with relative 
ease. Moreover, patients should 
maintain the right to have a degree 
of control over the records’ content. 
While it seems unreasonable to 
allow patients to modify or delete 
any of the content entered by 
healthcare professionals per se, it 
seems judicious to allow autono-
mous patients to review, annotate, 
or challenge their own electronic 
medical record. Furthermore, fed-
eral regulations must be reas-
sessed to determine what is con-
sidered valid informed consent 
for research using electronic 
health data specifically. Some 
HIEs are attempting to develop 
new consent processes to over-
come HIPAA compliance issues. 
Some are calling for a blanket 
“opt-in” or “opt-out” policy, 
while others suggest the inde-
pendent ability to exclude certain 
types of sensitive data in one’s 
own health record.31 Ideally, to 
maintain the highest level of pa-
tient autonomy, the patient would 
have full say as to what specific 
information may be shared and 
with whom it may be shared.  
Certain public health situ-
ations, though, necessitate the use 
of electronic health data without 
informed consent. This is particu-
larly true during public health 
emergencies. Syndromic surveil-
lance systems seek to use existing 
health data in real time to provide 
immediate analysis for early de-
tection of disease outbreaks, and 
to monitor disease trends.32 In the 
interest of population health, the 
HITECH framework allows for 
syndromic surveillance to notify 
public health officials of reporta-
ble conditions.33 
It is also necessary to note 
the point of “electronic exception-
alism.” There is a longstanding 
history of manual disease surveil-
lance. However, it seems more 
ethically unsettling when this pro-
cess is done with high technology 
tools that can quickly aggregate 
and share data in unprecedented 
ways. While critics may look at 
syndromic surveillance through 
EHR data as exceptional because 
of its electronic nature, its use may 
not be so different than traditional 
methods after all. There has been 
mandatory reporting of certain 
conditions to public health offi-
cials at the local and national level 
for decades before EHRs existed, 
including the reporting of drug-
resistant tuberculosis, certain can-
cers, and HIV. EHRs will make 
reporting of these conditions and 
others deemed necessary to protect 
public health easier, and may actu-
ally do a better job at protected 
patient health data by encrypting 
and preventing unauthorized ac-
cess through password protection. 
 
Meaningful for Whom? 
 
It is clear that the 
“meaningful use” of EHRs is on 
the rise, but is important to ques-
tion for whom is it meaningful, 
and how meaningful is it? Let us 
consider one of the primary goals 
of “meaningful use,” which is to 
provide patients with electronic 
resources to increase participation 
in their own care. Patients are pro-
vided with an electronic copy of 
their health information within 
three business days if requested, 
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 including diagnostic test results, 
medication lists, allergies, dis-
charge summaries, and proce-
dures.34 Accordingly, providers of-
ten offer patients access to their 
online personal health record 
(PHR). PHRs are largely secure as 
they are encrypted and password-
protected. However, it is important 
to note that patients need more than 
just Internet access and a very basic 
understanding of health information 
to fully benefit from PHRs.35  Not 
only must patients be able to read 
and interpret lab results; they must 
be willing and capable to act on the 
information he or she receives.  
This point has been largely neglect-
ed in discussions surrounding the 
HITECH Act. For those without 
access to the Internet, those with 
very limited health literacy, and 
those unable to act on that infor-
mation for financial or other rea-
sons, EHRs have limited to no di-
rect benefit. It is important to 
acknowledge these limitations and 
ethical concerns under the HITECH 
Act. In response, one must consider 
community outreach and education 
programs that focus on Internet and 
health literacy, rather than merely 
advertising new electronic and per-
sonal health record capabilities.36 
Many fear that patients will misun-
derstand or misinterpret infor-
mation if they read it without a 
medical professional to interpret it. 
It is possible that the HITECH Act 
granted healthcare providers a new 
ethical obligation to work with pa-
tients to ensure they understand 
these tools and how to use them.  
Furthermore, healthcare 
professionals run the risk of rely-
ing solely on PHRs to communi-
cate important health information 
to their patients. This stands to 
cause great harm to the doctor-
patient relationship. Electronic 
tools must not replace the face-to-
face communication between the 
healthcare provider and patient 
that is essential to maintaining 
trust and achieving improved 
health outcomes. 
 It has been well estab-
lished that the government has the 
police power authority to regulate 
for the safety and welfare for the 
population. However, it is im-
portant to consider from a bioeth-
ical perspective where the line 
ends between public health sur-
veillance and an intrusion on 
one’s own individual liberty and 
autonomy. On the other hand, it 
could be argued that it would be a 
“tragedy of the commons” if indi-
viduals independently acted ac-
cording to each one's self-interest 
and refused to be surveilled. To 
take a communitarian perspective, 
aggregation of public health data 
is an essential resource to public 
health officials and necessary for 
the welfare and beneficence of 
the population as a whole.  
 
Beneficence of Electronic Data 
in Medical Research 
 
Despite the ethical con-
cerns addressed above, the use of 
electronic health data is critical to 
ensuring patient health, improving 
our healthcare system, and making 
new scientific discoveries in this 
technological age. Critics may 
question whether EHRs are truly 
meaningful or whether it is an 
“excessive bureaucratic require-
ment to spend public dollars on 
doctors’ computer systems.”37  
The answer to this question can be 
discussed through the principle of 
justice. One can argue that it is 
ethical to expend public funds for 
EHR systems that provides for the 
greater good and benefits for the 
public as a whole. Data that is well
-structured and easily retrievable 
benefit clinicians, patients, and the 
greater population. These benefits 
include safer prescribing, preven-
tion of medication errors, epidemi-
ological tracking to protect popu-
lation health, and public medical 
error reporting. Furthermore, there 
is a clear demand to switch from 
outdated, burdensome, and ineffi-
cient clinical charting traditions to 
electronic format.  
 EHR adoption aims to re-
duce cost, which is a primary goal 
of health reform in the United 
States.38  The increase in infor-
mation available to clinicians can 
help prevent redundant or unnec-
essary tests and imaging. Further-
more, EHRs can provide point-of-
care clinical decision support 
(CDS) as doctors prescribe tests, 
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medications, and imaging requests, 
which can also help reduce costs. 
EHRs can also enable users to 
measure desired outcomes and re-
port this data more quickly and eas-
ily, saving both time and money. 
With regard to the costs associated 
with EHRs, studies demonstrate 
strong returns on financial invest-
ment that may be achieved follow-
ing EHR implementation.39 Other 
financial benefits include increased 
revenues due to improved care co-
ordination, averted costs of paper-
work, chart pulls, and billing errors, 
and fee-for-service savings includ-
ing the rate of new procedures and 
charge capture.40  
In addition, the secondary 
use of health record information is 
anticipated to become one of the 
healthcare industry’s greatest assets 
and the key to greater quality and 
cost savings over the next five 
years.41  A recent report by the 
McKinsey Global Institute, esti-
mates the potential annual value to 
the healthcare industry at over 300 
billion dollars.42 These savings in 
cost benefit both the patient and 
provider. 
There are also several pa-
tient-centered benefits that result 
from the “meaningful use” EHR 
data. Perhaps one of the most prom-
ising results of EHR data mining is 
the use of predictive modeling tech-
niques to identify medical condi-
tions and promote interventions be-
fore the onset of symptoms. Fur-
thermore, retrospective analysis of 
the health data mined from EHRs 
could expedite scientific discovery 
in medicine by providing valuable 
information for research. In addi-
tion, physicians’ access to data 
and analysis could demonstrate 
the efficacy of different treatment 
options across large populations, 
which could help treat and pre-
vent chronic conditions. Lastly, 
such data can be used to identify 
evidence-based best practices, 
identify potential patients for clin-
ical trials, and monitor patient 
compliance and drug safety. 
These measures show benefi-
cence towards the patient by 
providing better more individual-
ized care. 
Conclusion  
 
EHRs can facilitate the 
efficient delivery of healthcare in 
a cost-effective, safe, and patient-
centered way. The safety and pri-
vacy of patients and potential re-
search participants is of utmost 
concern and can be maintained 
while capitalizing on technologi-
cal advances to improve the Unit-
ed States healthcare system. It is 
possible to reconcile the use of 
electronic health data for research 
while maintaining respect for pa-
tient’s autonomy. Accomplishing 
this will require collaboration 
among ethicists, researchers, cli-
nicians, informatics specialists, 
and policy makers.43 By reevalu-
ating, clarifying, and enforcing 
HIPAA guidelines as they pertain 
specifically to secondary use, the 
federal government could point the 
healthcare field in a direction that 
both protects of patients’ privacy 
and autonomy while empowering 
researchers with valuable data 
sets. Permitting the establishment 
HIEs and data repositories of EHR 
data for research purposes has 
great potential for identifying evi-
dence-based best practices, moni-
toring patient compliance and drug 
safety, and showing the efficacy of 
different treatment options across 
large populations. However, we 
must provide patients with the 
right to dictate which information 
they choose to share and allow 
them to opt out of the platform to 
protect patient autonomy while 
optimizing the research potential 
of electronic health data. Moreo-
ver, EHRs cannot be considered a 
cure-all for patient health and we 
must acknowledge the effect it 
may have on the physician-patient 
relationship.  
The HITECH Act’s initia-
tives take us a step closer to Presi-
dent Obama’s stated goal of “an 
EHR for every American by 
2014.”44 The integration of HIT 
into our healthcare system is more 
than just a technological upgrade; 
it represents a fundamental change 
in our approach to healthcare prac-
tice. EHRs will continue to evolve 
as a critical component in the med-
ical field, and can be ethically in-
tegrated to deliver the highest 
quality healthcare to Americans in 
the 21st century. 
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